Abstract
A substantial number of patients undergoing percutaneous interventions have an impaired renal function, 1 Schuster S Koch A Burczyk U Schiele R Wagner S Zahn R Glunz H.G Heinrich F Stuby K Berg G et al. MITRA Study GroupTherapy of acute myocardial infarction impact of clinical trials on clinical practice The MITRA pilot phase. Z Kardiol. 1997; 86: 273-283 Crossref PubMed Scopus (63) Google Scholar a condition that is associated with a variety of changes in metabolic and hemostatic systems. 2 Mezzano D Tagle R Panes O Perez M Downey P Munoz B Aranda E Barja P Thambo S Gonzales F Mezzano S Pereira J Hemostatic disorders of uremia the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coaglation and fibrinolysis. J Thromb Haemost. 1996; 76: 312-321 Google Scholar There are only a few data on the application of abciximab in patients with impaired renal function. We used data from the Ludwigshafen IIb/IIIa-Antagonist Registry to analyze the safety and efficacy of abciximab for percutaneous coronary intervention (PCI) in patients with impaired renal function.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
